Unravel announces rareSHIFT™, an end-to-end solution for drug discovery
Retrieved on:
Monday, September 18, 2023
BOSTON, Sept. 18, 2023 /PRNewswire/ -- Unravel Biosciences, Inc., ("Unravel"), a therapeutics company leveraging a machine-learning model of human health to advance drugs for complex diseases, today announced the release of a groundbreaking new initiative, rareSHIFT™, to facilitate patient-centric drug discovery and translation with unprecedented speed.
Key Points:
- rareSHIFT™ provides industry and foundations access to Unravel's drug discovery engine to accelerate patient-centered drug development.
- BOSTON, Sept. 18, 2023 /PRNewswire/ -- Unravel Biosciences, Inc., ("Unravel"), a therapeutics company leveraging a machine-learning model of human health to advance drugs for complex diseases, today announced the release of a groundbreaking new initiative, rareSHIFT™, to facilitate patient-centric drug discovery and translation with unprecedented speed.
- "Unravel has developed a highly innovative and efficient drug discovery platform that serves as the engine for our pipeline of novel assets," said Neal I. Muni, M.D., MSPH, Chief Medical Officer at Unravel.
- rareSHIFT™ offers partners access to Unravel's full suite of industry-leading discovery and development capabilities, purposefully designed to provide a streamlined path to the clinic.